# Publications


1.Dey B, Chatterjee E, Pandey N, Singh H, Basak S, Kumar R, Sharma A, Bhalerao HA, Dharavath A, Lakshmi SS,
Singh PK, Sonti R, Naik PK, Doijad N, Guru SK. Glutamate Dehydrogenase 1 (GDH1) Sustains Triple-Negative Breast Cancer Persister Cell Survival by Coordinating Mitochondrial Fusion and Anaplerotic Flux. Cell Mol Life Sci. 2026; In press. EMID:82b61041582ff721.

2.Chatterjee E, Dey B, Basak S, Sharma R, Sharma A, Singh H, et al. The HDAC inhibitor RM-3-22 suppresses triple-negative breast cancer by uncoupling autophagy to drive FSP1-dependent ferroptosis. Transl Res. 2026; 10:1016.

3.Chatterjee E, Dey B, Sharma A, Dharavath A, Naik A, Singh H, et al. Autophagy-lysosomal dependency defines
a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer. Apoptosis. 2026; 31:136.

4.Dey B, Goel B, Chatterjee E, Singh H, Reddy HC, Cholkar A, et al. YAP inhibition by gloriosine unlocks autophagic cell death as an anticancer strategy in lung malignancies. Eur J Pharmacol. 2026; 1015:178582.

5.Mishra A, Yang WB, Liu TS, Thakur A, Grewal AS, Marczyk J, et al. Dual SYK-HDAC inhibitor elicits striking efficacy against acute myeloid leukemia: rational design, synthesis, and biological evaluation. J Med Chem. Published online 2026. doi: 10.1021/acs.jmedchem.6c00039.

6.Chatterjee E, Sharma R, Dey B, Singh H, Naik A, Khan A, et al. Anticancer activity of RM-3-22: a TAZQ-based
hydroxamic acid derivative targeting NSCLC in vitro and in vivo. Front Pharmacol. 2025; 16:1544666.

7.Mohammed S, Thakur S, Manhas D, et al. Discovery of 2-(4-ureido-piperidin-1-yl)-4-morpholinothieno[3,2-d] pyrimidines as orally bioavailable phosphoinositide-3-kinase inhibitors with in vitro and in vivo antitumor efficacy in triple-negative breast cancer. J Med Chem. 2025;68(20):21282-21317. doi: 10.1021/acs.jmedchem.5c01164.

8.Deb M, Singh H, Manhas D, Nandi U, Guru SK, Das P. Development of di-arylated 1,2,4-triazole-based derivatives as therapeutic agents against breast cancer: synthesis and biological evaluation. RSC Med Chem. 2024;15(9):3097-3113.

9.Sharma R, Chatterjee E, Jacob M, Sachin S, Vijayakameswara R, Pan CH, et al. Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. Eur J Med Chem. 2022;240.

10.Samanta S, Guru SK, Elaimy AL, Amante JJ, Ou J, Yu J, et al. IMP3 stabilization of WNT5B mRNA facilitates
TAZ activation in breast cancer. Cell Rep. 2018; 23:2559-2567.

11.Elaimy AL, Guru SK, et al. VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-

mediated repression of the Rac GAP β2-chimaerin. Sci Signal. 2018;11(528): eaao6897.

12.Bharate SB, Kumar V, Jain SK, Mintoo MJ, Guru SK, Nuthakki VK, et al. Discovery and preclinical development
of IIIM-290, an orally active potent cyclin-dependent kinase inhibitor. J Med Chem. 2018;61(4):1664-1687.

13.Singh U, Chashoo G, Khan SU, Mahajan P, Nargotra A, Mahajan G, et al. Design of novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model. J Med Chem. 2017;60(23):9470-9489.

14.Yadav RR, Guru SK, et al. 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. Eur J Med Chem. 2016; 122:731-743.

15.Pathania AS, Guru SK, Kumar S, Kumar A, Ahmad M, Bhushan S, et al. Interplay between cell cycle and autophagy induced by boswellic acid analog. Sci Rep. 2016; 6:33146.

16.Hussain A, Qazi AK, Mupparapu N, Guru SK, et al. Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and decreases colorectal cancer growth. Cancer Lett. 2016; 374:250-260.

17.Guru SK, et al. Secalonic acid-D represses HIF1α/VEGF-mediated angiogenesis by regulating the Akt/mTOR/p70S6K signaling cascade. Cancer Res. 2015; 75:2886-2896.

18.Pathania AS, Wani ZA, Guru SK, Kumar S, Bhushan S, Korkaya H, et al. The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors. Mol Cancer. 2015; 14:6.

19.Kumar S, Guru SK, Pathania AS, Kumar A, Bhushan S, Malik F. Autophagy triggered by magnolol derivative negatively regulates angiogenesis. Cell Death Dis. 2013;4: e889.

20.Kumar S, Kumar A, Pathania AS, Guru SK, Jada S, Sharma PR, et al. Tiron and Trolox potentiate the autophagic
cell death induced by magnolol analog Ery5 by activation of Bax in HL-60 cells. Apoptosis. 2013;18(5):605-617.

21.Pathania AS, Joshi A, Kumar S, Guru SK, et al. Reversal of boswellic acid analog BA145-induced caspase-dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. Apoptosis. 2013;18(12):1561-1573.